Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes.
In clinical trials, Xultophy reduced A1C and lowered blood sugar for 24 hours, according to Nordisk.
“Continuing research and development to find safe and effective medications for people living with diabetes is important, particularly for those who require additional A1C-lowering options,” Dr. Steve Edelman, founder & director of Taking Control of Your Diabetes, said in prepared remarks. “Now that Xultophy 100/3.6 is available, patients with Type II diabetes who are uncontrolled on basal insulin have a new combination that can help achieve their individualized treatment goals.”
The therapy is administered once a day using a pre-filled pen.
Also today, Nordisk reported its 1st quarter earnings for 2017. Shares in the company rose after the insulin-maker beat expectations on The Street.
